This combined therapy can provide assistance for improving the objective response rate (CR + PR) of HCC, prolonging long term survival time (12, 18, 24, 36 months), enhancing life quality (QoL scores and KPS) of patients, increasing some laboratory index (AFP) and immune functions (CD3+, CD4+, CD4+/CD8+, NK) and reducing some adverse effects (WBC decrease, gastrointestinal adverse effects). This evidence concerns the gene CD8A and hepatocellular carcinoma.